AZD5335 + carboplatin + bevacizumab

AZD5335 + carboplatin + bevacizumab is an investigational anti-cancer combination therapy under evaluation primarily for advanced solid tumors, especially ovarian cancer. AZD5335 is a folate receptor alpha-targeted antibody-drug conjugate (ADC) designed to deliver a TOP1 inhibitor cytotoxic payload selectively to cancer cells expressing folate receptor alpha, thereby minimizing off-target toxicity. Carboplatin is a platinum-based alkylating chemotherapeutic that causes DNA crosslinking and apoptosis. Bevacizumab is a humanized monoclonal antibody that targets vascular endothelial growth factor A (VEGF-A), inhibiting angiogenesis. The combination is being studied for enhanced anti-tumor efficacy through complementary mechanisms: direct cytotoxicity (AZD5335, carboplatin) and inhibition of tumor angiogenesis (bevacizumab)[2][3][8].